Iyyapu Krishna Mohan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iyyapu Krishna Mohan has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Siraj Ahmed Khan
Department of Biochemistry, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
7 shared publicationsK. S. S. Sai Baba
Department of Biochemistry, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
3 shared publicationsKss Sai Baba
Nizams Inst Med Sci, Dept Biochem, Hyderabad 500082, Telangana, India
3 shared publicationsN. N. Sreedevi
Department of Biochemistry, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
3 shared publicationsNoorjahan Mohammed
Department of Biochemistry, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
3 shared publicationsDunna Sabitha
Department of Biochemistry, GIMSR, Visakhapatnam, Andhra Pradesh, India
2 shared publications
Latest Publications
- Open Access
- 13 December 2024
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 16, 543-551
Diagnostic utility of antibodies to structural protein and fibroblast intermediate filament, vimentin, in the detection of rheumatoid arthritis
Objectives: This study aimed to evaluate the specificity and sensitivity of serum anti-mutated citrullinated vimentin (MCV) antibodies in rheumatoid arthritis (RA) patients and to determine their diagnostic utility compared to anti-cyclic citrullinated peptide antibodies and rheumatoid factor (RF). Materials and Methods: This study employs a cross-sectional design. Patients were categorized using the 2010 American College of Rheumatology RA criteria. The first group consists of 60 cases, of which 30 are seropositive RA, and 30 are seronegative RA. The second group consists of 60 controls, of which 30 are RF-positive connective tissue disorder (CTD) cases and 30 are healthy. Enzyme-linked immunosorbent assay kits were used to quantify the amounts of anti-MCV and anti-cyclic citrullinated protein. Statistical analysis: Version 9 of GraphPad Prism was utilized for doing the statistical analysis. We employed the Kolmogorov-Smirnov test, one-way ANOVA, Student’s t-test, the Kruskal-Walli or Mann-Whitney U tests, and Fisher’s exact or Chi-Square tests for statistical analysis. To study associations between variables, Spearman’s correlation test is used. Results: The anti-MCV (ng/mL) median concentrations in healthy controls, CTD controls, seronegative RA, and seropositive RA are 1.487, 5.294, 10.51, and 7.985, respectively, and show a significant increase (P < 0.05) in comparison to healthy controls. Seropositive and seronegative RA subjects did not differ statistically significantly in their anti-MCV levels. According to receiver operating characteristic analysis results, anti-MCV has 100% sensitivity and 83.33% specificity in seropositive RA cases with an optimal cutoff of 6.38 ng/mL and 100% sensitivity and 83.33% specificity in RF-negative RA cases with an ideal cutoff of 6.63 ng/mL. Conclusions: The higher levels found in both seropositive and seronegative cases of RA suggest the possibility of using serum anti-MCV as a sensitive RA marker. Anti-MCV may help in the diagnosis of RA, especially seronegative arthritis.
- 13 December 2024
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 16, 543-551
Open AccessDiagnostic utility of antibodies to structural protein and fibroblast intermediate filament, vimentin, in the detection of rheumatoid arthritis
Objectives: This study aimed to evaluate the specificity and sensitivity of serum anti-mutated citrullinated vimentin (MCV) antibodies in rheumatoid arthritis (RA) patients and to determine their diagnostic utility compared to anti-cyclic citrullinated peptide antibodies and rheumatoid factor (RF). Materials and Methods: This study employs a cross-sectional design. Patients were categorized using the 2010 American College of Rheumatology RA criteria. The first group consists of 60 cases, of which 30 are seropositive RA, and 30 are seronegative RA. The second group consists of 60 controls, of which 30 are RF-positive connective tissue disorder (CTD) cases and 30 are healthy. Enzyme-linked immunosorbent assay kits were used to quantify the amounts of anti-MCV and anti-cyclic citrullinated protein. Statistical analysis: Version 9 of GraphPad Prism was utilized for doing the statistical analysis. We employed the Kolmogorov-Smirnov test, one-way ANOVA, Student’s t-test, the Kruskal-Walli or Mann-Whitney U tests, and Fisher’s exact or Chi-Square tests for statistical analysis. To study associations between variables, Spearman’s correlation test is used. Results: The anti-MCV (ng/mL) median concentrations in healthy controls, CTD controls, seronegative RA, and seropositive RA are 1.487, 5.294, 10.51, and 7.985, respectively, and show a significant increase (P < 0.05) in comparison to healthy controls. Seropositive and seronegative RA subjects did not differ statistically significantly in their anti-MCV levels. According to receiver operating characteristic analysis results, anti-MCV has 100% sensitivity and 83.33% specificity in seropositive RA cases with an optimal cutoff of 6.38 ng/mL and 100% sensitivity and 83.33% specificity in RF-negative RA cases with an ideal cutoff of 6.63 ng/mL. Conclusions: The higher levels found in both seropositive and seronegative cases of RA suggest the possibility of using serum anti-MCV as a sensitive RA marker. Anti-MCV may help in the diagnosis of RA, especially seronegative arthritis.
- 1 June 2024
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 18 (6) , BC7-BC11
Iron Deficiency and Hypoferritinaemia in Patients with Subclinical Hypothyroidism: A Retrospective Observational Study
Introduction: Iron acts as a cofactor in Thyroid Peroxidase (TPO) activity, and low iron levels can impact thyroid hormone metabolism. The function of ferritin and iron has been extensively documented in various studies in patients with Overt Hypothyroidism (OH), but their role in Subclinical Hypothyroidism (SH) remains largely unexplored. Aim: To evaluate the serum ferritin and iron levels in patients who have SH. Materials and Methods: A retrospective observational study was conducted between March 2018 and October 2018 at the Biochemistry Department of Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India. For the study, a total of 100 cases of SH were enrolled, and these patients were matched in terms of age and sex with 50 healthy controls. A fasting sample was obtained and analysed for serum ferritin, Total Iron Binding Capacity (TIBC), TT3, TT4, and Thyroid Stimulating Hormone (TSH). MedCalc software was used to perform statistical analysis. Results: In the SH group, there were 32 males (32%) and 68 females (68%); in the control group, there were 21 males (42%) and 29 females (58%). The median values of TT3 (nmol/L), TT4 (μg/ dL), and TSH (μIU/mL) were 1.55 (1.4-1.95), 7.8 (5.9-9.75), and 3 (1.9-3.75) for controls, and 1.4 (1.1-1.75), 6.85 (5.5-8.15), and 6.2 (4.8-8.05), respectively, for cases. In comparison to controls, the TSH level was significantly higher (p<0.0001) in cases. The median iron (μg/dL), ferritin (ng/mL), TIBC (μg/dL), and % saturation in cases were 56.5 (41.5-82), 110 (31.5-194.5), 329 (258-390), and 19 (11.25-26.75), respectively, while in controls they were 84 (68.5- 96.5), 195 (121.5-338.5), 233 (188.5-294), and 25 (18-37.5). There was a significant decrease in iron level (p<0.00001), % saturation (<0.00001), and ferritin level (p<0.00001), and a significant increase in TIBC (p<0.0001) in cases when compared to controls. Conclusion: In conclusion, the present study showed a significant negative correlation between SH and iron deficiency. Patients with this condition should be evaluated for ferritin and iron levels and treated appropriately to prevent hypothyroidism.
- 1 June 2024
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 18 (6) , BC7-BC11
Iron Deficiency and Hypoferritinaemia in Patients with Subclinical Hypothyroidism: A Retrospective Observational Study
Introduction: Iron acts as a cofactor in Thyroid Peroxidase (TPO) activity, and low iron levels can impact thyroid hormone metabolism. The function of ferritin and iron has been extensively documented in various studies in patients with Overt Hypothyroidism (OH), but their role in Subclinical Hypothyroidism (SH) remains largely unexplored. Aim: To evaluate the serum ferritin and iron levels in patients who have SH. Materials and Methods: A retrospective observational study was conducted between March 2018 and October 2018 at the Biochemistry Department of Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India. For the study, a total of 100 cases of SH were enrolled, and these patients were matched in terms of age and sex with 50 healthy controls. A fasting sample was obtained and analysed for serum ferritin, Total Iron Binding Capacity (TIBC), TT3, TT4, and Thyroid Stimulating Hormone (TSH). MedCalc software was used to perform statistical analysis. Results: In the SH group, there were 32 males (32%) and 68 females (68%); in the control group, there were 21 males (42%) and 29 females (58%). The median values of TT3 (nmol/L), TT4 (μg/ dL), and TSH (μIU/mL) were 1.55 (1.4-1.95), 7.8 (5.9-9.75), and 3 (1.9-3.75) for controls, and 1.4 (1.1-1.75), 6.85 (5.5-8.15), and 6.2 (4.8-8.05), respectively, for cases. In comparison to controls, the TSH level was significantly higher (p<0.0001) in cases. The median iron (μg/dL), ferritin (ng/mL), TIBC (μg/dL), and % saturation in cases were 56.5 (41.5-82), 110 (31.5-194.5), 329 (258-390), and 19 (11.25-26.75), respectively, while in controls they were 84 (68.5- 96.5), 195 (121.5-338.5), 233 (188.5-294), and 25 (18-37.5). There was a significant decrease in iron level (p<0.00001), % saturation (<0.00001), and ferritin level (p<0.00001), and a significant increase in TIBC (p<0.0001) in cases when compared to controls. Conclusion: In conclusion, the present study showed a significant negative correlation between SH and iron deficiency. Patients with this condition should be evaluated for ferritin and iron levels and treated appropriately to prevent hypothyroidism.
- Open Access
- 18 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e50719
Clinical Utility of Soluble Lectin Type Oxidized Low-Density Lipoprotein Receptor as a Biomarker for Myocardial Infarction and Stable Angina
Background and objectives Endothelial soluble lectin-type oxidized low-density lipoprotein receptor 1 (sLOX-1) recognizes oxidized low-density lipoprotein (LDL) and triggers downstream signaling leading to atherosclerosis. The objective of this study was to demonstrate the utility of sLOX-1 as a biomarker for detecting acute myocardial infarction (MI) and stable angina (SA) and to develop a diagnostic algorithm for distinguishing coronary vasospasm from coronary plaque rupture. Methods We enrolled 62 patients who underwent diagnostic coronary angiography (CAG) and 30 healthy controls (21 men and nine women) and measured sLOX-1, troponin I, and cardiac myosin-binding protein C (c-MyBPC) using commercial kits. Results Patients with MI exhibited higher sLOX-1 levels (301.55 ± 196.16 pg/ml) than patients with stable angina (220.76 ± 103.65 pg/ml) and healthy controls (121.14 ± 77.10, F: 10.55, p<0.001). Although higher troponin I levels were detected in MI patients (263.00 ± 493.00 vs. 3.19 ± 2.15 ng/ml, p=0.0019), no significant elevation was observed in SA patients (1.91 ± 0.79 ng/ml). Plasma sLOX-1 levels showed a positive association with age (r=0.37, p=0.003), but not with gender (r=0.04, p=0.75). Troponin I showed no association with age (r=0.12, p=0.36) or gender (r=0.06, p=0.62). Receiver operating characteristic (ROC) curves revealed that among the three biomarkers, troponin-I showed a higher area under the curve (AUC) (AUC: 0.941), followed by sLOX-1 (AUC: 0.888), while c-MyBPC showed no clinical utility in the detection of MI (AUC: 0.666). Conclusions A marked elevation of sLOX-1 can detect MI and differentiate the presence or absence of plaque rupture, along with diagnosing stable angina.
- 18 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e50719
Open AccessClinical Utility of Soluble Lectin Type Oxidized Low-Density Lipoprotein Receptor as a Biomarker for Myocardial Infarction and Stable Angina
Background and objectives Endothelial soluble lectin-type oxidized low-density lipoprotein receptor 1 (sLOX-1) recognizes oxidized low-density lipoprotein (LDL) and triggers downstream signaling leading to atherosclerosis. The objective of this study was to demonstrate the utility of sLOX-1 as a biomarker for detecting acute myocardial infarction (MI) and stable angina (SA) and to develop a diagnostic algorithm for distinguishing coronary vasospasm from coronary plaque rupture. Methods We enrolled 62 patients who underwent diagnostic coronary angiography (CAG) and 30 healthy controls (21 men and nine women) and measured sLOX-1, troponin I, and cardiac myosin-binding protein C (c-MyBPC) using commercial kits. Results Patients with MI exhibited higher sLOX-1 levels (301.55 ± 196.16 pg/ml) than patients with stable angina (220.76 ± 103.65 pg/ml) and healthy controls (121.14 ± 77.10, F: 10.55, p<0.001). Although higher troponin I levels were detected in MI patients (263.00 ± 493.00 vs. 3.19 ± 2.15 ng/ml, p=0.0019), no significant elevation was observed in SA patients (1.91 ± 0.79 ng/ml). Plasma sLOX-1 levels showed a positive association with age (r=0.37, p=0.003), but not with gender (r=0.04, p=0.75). Troponin I showed no association with age (r=0.12, p=0.36) or gender (r=0.06, p=0.62). Receiver operating characteristic (ROC) curves revealed that among the three biomarkers, troponin-I showed a higher area under the curve (AUC) (AUC: 0.941), followed by sLOX-1 (AUC: 0.888), while c-MyBPC showed no clinical utility in the detection of MI (AUC: 0.666). Conclusions A marked elevation of sLOX-1 can detect MI and differentiate the presence or absence of plaque rupture, along with diagnosing stable angina.
- 4 November 2022
- Published by Elsevier
- Vol. 112, 205-248
Advances in congestive heart failure biomarkers
- 4 November 2022
- Published by Elsevier
- Vol. 112, 205-248
Advances in congestive heart failure biomarkers
- 13 September 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (1) , 110-117
Clinical Utility of Pro-inflammatory Oligomeric Glycoprotein Tenascin-C in the Diagnosis of Seropositive and Seronegative Rheumatoid Arthritis
Owing to limited usefulness of Rheumatoid Factor and anti-CCP in rheumatoid arthritis, there is a need to identify a more sensitive and specific biomarker to detect rheumatoid arthritis (RA), particularly seronegative RA cases. Tenascin-C is an extracellular matrix glycoprotein, which has been implicated in the pathophysiology of RA. The objective of our study was to evaluate the diagnostic utility of serum Tenascin-C in seropositive and seronegative rheumatoid arthritis patients. We conducted a cross-sectional case control study. Sixty patients who fulfilled the ACR 2010 criteria for rheumatoid arthritis were included in the study. Thirty patients were found to be positive for RF and/or anti-CCP and 30 were negative for both RF and anti-CCP. Thirty age and gender-matched healthy subjects were taken as controls. Serum Tenascin-C was measured by quantitative sandwich enzyme immunoassay technique. The mean serum concentration of Tenascin-C in controls, seronegative and seropositive cases was 0.66 ng/ml, 20.54 ng/ml and 23.42 ng/ml, respectively. Tenascin-C levels were significantly higher in RA cases compared to controls (p < 0.0001). There was no significant difference in Tenascin-C between seropositive and seronegative cases (p = 0.603). ROC curve analysis showed a sensitivity of 96.6% and specificity of 100% with AUC of 0.98 at 2.21 ng/ml as cut-off value for diagnosing RA. Tenascin-C is elevated in both seronegative and seropositive RA, which indicates that it can be used as a sensitive marker for RA. The addition of Tenascin-C to the existing RF and anti-CCP may help in identifying a large number of patients with RA, particularly seronegative rheumatoid arthritis cases.
- 13 September 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 39 (1) , 110-117
Clinical Utility of Pro-inflammatory Oligomeric Glycoprotein Tenascin-C in the Diagnosis of Seropositive and Seronegative Rheumatoid Arthritis
Owing to limited usefulness of Rheumatoid Factor and anti-CCP in rheumatoid arthritis, there is a need to identify a more sensitive and specific biomarker to detect rheumatoid arthritis (RA), particularly seronegative RA cases. Tenascin-C is an extracellular matrix glycoprotein, which has been implicated in the pathophysiology of RA. The objective of our study was to evaluate the diagnostic utility of serum Tenascin-C in seropositive and seronegative rheumatoid arthritis patients. We conducted a cross-sectional case control study. Sixty patients who fulfilled the ACR 2010 criteria for rheumatoid arthritis were included in the study. Thirty patients were found to be positive for RF and/or anti-CCP and 30 were negative for both RF and anti-CCP. Thirty age and gender-matched healthy subjects were taken as controls. Serum Tenascin-C was measured by quantitative sandwich enzyme immunoassay technique. The mean serum concentration of Tenascin-C in controls, seronegative and seropositive cases was 0.66 ng/ml, 20.54 ng/ml and 23.42 ng/ml, respectively. Tenascin-C levels were significantly higher in RA cases compared to controls (p < 0.0001). There was no significant difference in Tenascin-C between seropositive and seronegative cases (p = 0.603). ROC curve analysis showed a sensitivity of 96.6% and specificity of 100% with AUC of 0.98 at 2.21 ng/ml as cut-off value for diagnosing RA. Tenascin-C is elevated in both seronegative and seropositive RA, which indicates that it can be used as a sensitive marker for RA. The addition of Tenascin-C to the existing RF and anti-CCP may help in identifying a large number of patients with RA, particularly seronegative rheumatoid arthritis cases.
- Open Access
- 17 August 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (01) , 020-024
Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors
Introduction Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors. Aim To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA). Results Mammaglobin and CEA levels were elevated in breast cancer patients, followed by benign breast tumors when compared with controls (P < 0.000001). Mammaglobin showed 81.5% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 88.9% negative predictive value (NPV). CEA showed 88.9% sensitivity, 82.5% specificity, 77.4% PPV, and 91.7% NPV. The area under the curve was the highest for MAM (0.892), followed by CEA (0.889) and CA 15–3 (0.555). CA15–3 showed poor diagnostic efficacy. Combined receiver operating characteristic (ROC) curve of the biomarkers MAM and CEA had an AUC of 0.913. Conclusion Mammaglobin proved to be an efficacious biomarker in diagnosing breast cancer.
- 17 August 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (01) , 020-024
Open AccessEvaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors
Introduction Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors. Aim To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA). Results Mammaglobin and CEA levels were elevated in breast cancer patients, followed by benign breast tumors when compared with controls (P < 0.000001). Mammaglobin showed 81.5% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 88.9% negative predictive value (NPV). CEA showed 88.9% sensitivity, 82.5% specificity, 77.4% PPV, and 91.7% NPV. The area under the curve was the highest for MAM (0.892), followed by CEA (0.889) and CA 15–3 (0.555). CA15–3 showed poor diagnostic efficacy. Combined receiver operating characteristic (ROC) curve of the biomarkers MAM and CEA had an AUC of 0.913. Conclusion Mammaglobin proved to be an efficacious biomarker in diagnosing breast cancer.
- Open Access
- 29 June 2021
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 9 (1) , 15-21
Unexpected Detection of Abnormal Hemoglobin Variants During Routine HbA1c Analysis by HPLC Technique: Challenges and Opportunities in HbA1c Testing
Background: Glycated Hemoglobin A1c (HbA1c) assay is most widely used in diabetic patients for assessing long-term control of glycemia. The presence of hemoglobin variants may be an incidental finding and can interfere with HbA1c measurements. The aim of the present study is to investigate the prevalence and impact of interference of different abnormal hemoglobin variants on HbA1c measurements during routine HbA1c testing. Methods: A total of 12,092 HbA1c samples were collected from January to August 2018. HbA1c quantification was carried out on a Variant II Bio-Rad’s HPLC analyzer. Abnormal chromatograms were further analyzed using the extended-run high-pressure liquid chromatography (HPLC) analysis in the A2/F mode. Results: The samples were examined for presence of abnormal variants. Samples producing abnormal chromatograms were further analyzed in A2/F mode to characterize hemoglobin variants. Abnormal variants were identified in 126 (1%) samples, and 74 (0.59%) sickle cell traits (SCT) were the most common variant in our findings. Moreover, 30 (0.24%) cases were eluted in the variant window in A1c mode, which on further analysis were found to be Hb E & Hb D traits. Furthermore, 3 (0.02%) cases were eluted at a RT <1 min as (unknown) and identified as Hb H. Also,19 (0.15%) samples were eluted in the P3 window at different retention times. Conclusion: Observing each chromatograph after the analysis can help us in identifying silent hemoglobin variants in routine HbA1c testing. Knowledge and awareness of common hemoglobin variants affecting measurement of HbA1c is imperative to avoid reporting of falsely low HbA1c values in diabetic population.
- 29 June 2021
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 9 (1) , 15-21
Open AccessUnexpected Detection of Abnormal Hemoglobin Variants During Routine HbA1c Analysis by HPLC Technique: Challenges and Opportunities in HbA1c Testing
Background: Glycated Hemoglobin A1c (HbA1c) assay is most widely used in diabetic patients for assessing long-term control of glycemia. The presence of hemoglobin variants may be an incidental finding and can interfere with HbA1c measurements. The aim of the present study is to investigate the prevalence and impact of interference of different abnormal hemoglobin variants on HbA1c measurements during routine HbA1c testing. Methods: A total of 12,092 HbA1c samples were collected from January to August 2018. HbA1c quantification was carried out on a Variant II Bio-Rad’s HPLC analyzer. Abnormal chromatograms were further analyzed using the extended-run high-pressure liquid chromatography (HPLC) analysis in the A2/F mode. Results: The samples were examined for presence of abnormal variants. Samples producing abnormal chromatograms were further analyzed in A2/F mode to characterize hemoglobin variants. Abnormal variants were identified in 126 (1%) samples, and 74 (0.59%) sickle cell traits (SCT) were the most common variant in our findings. Moreover, 30 (0.24%) cases were eluted in the variant window in A1c mode, which on further analysis were found to be Hb E & Hb D traits. Furthermore, 3 (0.02%) cases were eluted at a RT <1 min as (unknown) and identified as Hb H. Also,19 (0.15%) samples were eluted in the P3 window at different retention times. Conclusion: Observing each chromatograph after the analysis can help us in identifying silent hemoglobin variants in routine HbA1c testing. Knowledge and awareness of common hemoglobin variants affecting measurement of HbA1c is imperative to avoid reporting of falsely low HbA1c values in diabetic population.
- 1 August 2020
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 14 (8)
Study of Glycation of Transferrin and its Effect on Biomarkers of Iron Status in Uncontrolled Diabetes Mellitus Patients
Introduction: Diabetes Mellitus (DM) is a metabolic condition linked by the inability to produce enough insulin and/or to respond to insulin. This can lead to a number of acute and chronic health problems. In erythrocytes, transferrin is the main source of iron. Alterations in transferrin glycation affect transferrin saturation because the affinity of transferrin for Fe3+ is extremely high but it decreases progressively with increasing glycation. Aim: To investigate the influence of uncontrolled diabetes on transferrin glycation, iron metabolism and status. Materials and Methods: A total of 136 samples from 3 groups of HbA1c levels (8-uncontrolled DM) were studied for the correlation pattern of iron with other variables. Chi square test and student's t-test were performed o reveal the association between serum free iron levels and other variables with DM. Results: Serum iron has shown to be depleted significantly (p=0.02) along with percentage saturation (p=0.0006) with increase in diabetic severity. No significant differences were observed in serum ferritin in controlled DM and uncontrolled samples. Total Iron Binding Capacity (TIBC) was found to be significantly increased in uncontrolled DM samples (p=0.01). Abnormal transferrin was observed uncontrolled diabetes with subsequent depletion in transferrin, which in turn results in low serum iron, lower percentage saturation and high TIBC. Conclusion: Uncontrolled diabetes affects the glycation of transferrin also thus perturbating iron metabolism. This study emphasises the need to monitor transferrin glycation status and iron deficiency anaemia in subjects with uncontrolled diabetes.
- 1 August 2020
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 14 (8)
Study of Glycation of Transferrin and its Effect on Biomarkers of Iron Status in Uncontrolled Diabetes Mellitus Patients
Introduction: Diabetes Mellitus (DM) is a metabolic condition linked by the inability to produce enough insulin and/or to respond to insulin. This can lead to a number of acute and chronic health problems. In erythrocytes, transferrin is the main source of iron. Alterations in transferrin glycation affect transferrin saturation because the affinity of transferrin for Fe3+ is extremely high but it decreases progressively with increasing glycation. Aim: To investigate the influence of uncontrolled diabetes on transferrin glycation, iron metabolism and status. Materials and Methods: A total of 136 samples from 3 groups of HbA1c levels (8-uncontrolled DM) were studied for the correlation pattern of iron with other variables. Chi square test and student's t-test were performed o reveal the association between serum free iron levels and other variables with DM. Results: Serum iron has shown to be depleted significantly (p=0.02) along with percentage saturation (p=0.0006) with increase in diabetic severity. No significant differences were observed in serum ferritin in controlled DM and uncontrolled samples. Total Iron Binding Capacity (TIBC) was found to be significantly increased in uncontrolled DM samples (p=0.01). Abnormal transferrin was observed uncontrolled diabetes with subsequent depletion in transferrin, which in turn results in low serum iron, lower percentage saturation and high TIBC. Conclusion: Uncontrolled diabetes affects the glycation of transferrin also thus perturbating iron metabolism. This study emphasises the need to monitor transferrin glycation status and iron deficiency anaemia in subjects with uncontrolled diabetes.
- Open Access
- 1 August 2020
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 12 (02) , 126-132
Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
Background Heart failure is a complex cardiovascular disease with a variety of etiologies and heterogeneity. The N-terminal pro-B-type natriuretic peptide (NT-proBNP) value has limited usefulness in diagnosing heart failure with preserved ejection fraction (HFpEF). Aim The aim of the present study is to evaluate serum Galectin-3 as a diagnostic biomarker in patients with HFpEF and to compare Galectin-3 with NT-proBNP levels. Materials and Methods A cross-sectional case–control study including 63 cases of heart failure with ejection fraction ≥50% confirmed by echocardiography. NT-proBNP levels in serum were measured by electrochemiluminescence immunoassay and Galectin-3 levels in serum were measured by using an enzyme-linked-immunosorbent serologic assay kit. Results The median levels of serum Galectin-3 and NT-proBNP in patients were significantly higher than those of controls (26.59 vs. 5.27 and 927 vs. 49.3, p < 0.0001). A positive correlation was observed between serum levels of Galection-3 and NT-ProBNP (r: 0.21, p = 0.048). At cut-off values of 10.1 ng/mL and 160 pg/mL, serum Galectin-3 has 77.78% sensitivity, 95% specificity with an area under the curve (AUC) of 0.93, and serum NT-proBNP has 71.43% sensitivity, 100% specificity with an AUC of 0.87, respectively, for diagnosing HFpEF. The comparison of receiver operating characteristics curves showed that Galectin-3 has better AUC compared with NT-proBNP in diagnosing HFpEF. Serum Galectin-3 showed a positive correlation with NT-proBNP and lipid parameters. Conclusion Galectin-3 with higher sensitivity and AUC can be used as a valuable biomarker for the diagnosis of HFpEF. Simultaneous testing of both Galectin-3 and NT-proBNP can further improve the detection of patients with HFpEF.
- 1 August 2020
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 12 (02) , 126-132
Open AccessEvaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
Background Heart failure is a complex cardiovascular disease with a variety of etiologies and heterogeneity. The N-terminal pro-B-type natriuretic peptide (NT-proBNP) value has limited usefulness in diagnosing heart failure with preserved ejection fraction (HFpEF). Aim The aim of the present study is to evaluate serum Galectin-3 as a diagnostic biomarker in patients with HFpEF and to compare Galectin-3 with NT-proBNP levels. Materials and Methods A cross-sectional case–control study including 63 cases of heart failure with ejection fraction ≥50% confirmed by echocardiography. NT-proBNP levels in serum were measured by electrochemiluminescence immunoassay and Galectin-3 levels in serum were measured by using an enzyme-linked-immunosorbent serologic assay kit. Results The median levels of serum Galectin-3 and NT-proBNP in patients were significantly higher than those of controls (26.59 vs. 5.27 and 927 vs. 49.3, p < 0.0001). A positive correlation was observed between serum levels of Galection-3 and NT-ProBNP (r: 0.21, p = 0.048). At cut-off values of 10.1 ng/mL and 160 pg/mL, serum Galectin-3 has 77.78% sensitivity, 95% specificity with an area under the curve (AUC) of 0.93, and serum NT-proBNP has 71.43% sensitivity, 100% specificity with an AUC of 0.87, respectively, for diagnosing HFpEF. The comparison of receiver operating characteristics curves showed that Galectin-3 has better AUC compared with NT-proBNP in diagnosing HFpEF. Serum Galectin-3 showed a positive correlation with NT-proBNP and lipid parameters. Conclusion Galectin-3 with higher sensitivity and AUC can be used as a valuable biomarker for the diagnosis of HFpEF. Simultaneous testing of both Galectin-3 and NT-proBNP can further improve the detection of patients with HFpEF.
- Open Access
- 1 June 2019
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 13 (6) , BC21-BC24
Correlation between Total Plasma Homocysteine Levels and Oxidative DNA Damage in Healthy Indian Adults
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
- 1 June 2019
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 13 (6) , BC21-BC24
Open AccessCorrelation between Total Plasma Homocysteine Levels and Oxidative DNA Damage in Healthy Indian Adults
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.